search
Back to results

AuriNovo for Auricular Reconstruction

Primary Purpose

Microtia

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
AuriNovo
Sponsored by
3DBio Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Microtia focused on measuring ear reconstruction

Eligibility Criteria

6 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Pediatric children 6-11, adolescents 12-16, or adults 17-25 years old
  2. Born with unilateral microtia Grade II, III, or IV
  3. No previous surgical procedure for auricular reconstruction
  4. Have undergone an audiological assessment prior to enrollment and surgeon confirmation that study participation will not preclude future hearing correction options
  5. Normal or near normal hairline position
  6. Able to adhere to the follow-up schedule and post-surgery care instructions
  7. Ability for the subject and/or guardian to understand and give informed consent
  8. Healthy subjects with no history of cancer, problematic wound healing, or immune disorders

Exclusion Criteria:

  1. Previous cochlear implant surgery
  2. Patients with prior surgery in the temporal, parietal, or mastoid regions of the affected side that resulted in scarring that may affect the outcome of microtia reconstruction surgery.
  3. Sensitivity to broad-spectrum aminoglycoside antibiotics containing any of the following: streptomycin, gentamycin tobramycin, amikacin, kanamycin, neomycin, or plazomicin.
  4. Sensitivity to materials of porcine origin including pork products. For subjects with no known exposure to porcine materials including pork products, sensitivity as confirmed at baseline through a positive porcine skin sensitivity test.
  5. Patients previously diagnosed/evaluated for any of the following syndromes:

    1. CHARGE (Coloboma, Heart defect, choanal Atresia, Retarded growth and development, Genital hypoplasia, Ear anomalies) syndrome,
    2. Branchio-oto-renal (BOR) syndrome
    3. Patients with renal dysfunction of any etiology
  6. Patients with abnormal renal function determined at baseline with a blood test.
  7. Patients with a history of keloid formation.
  8. Patients with current skin infection.
  9. Patients on immunosuppressants.
  10. Any cognitive disorders where the patient would not be able to complete subject assessment questionnaires.
  11. Lifestyle activities likely to affect healing or ability to adhere to the protocol (e.g., active contact sports and protective gear interferes with wearing post-operative ear protection)
  12. Patients requiring chronic use of any headgear (e.g., CPAP) that would interfere with the ability to wear post-operative ear protection.
  13. Pregnant females (a negative pregnancy test is required for females with reproductive potential)
  14. Female patients who are nursing/lactating
  15. Patients of reproductive potential (male and female) unwilling to use effective contraception during the first post-operative year.

    For this first-in-human study, microtia patients with significant craniofacial asymmetries or deformities from other syndromes will be excluded in order to aid initial assessments of efficacy of AuriNovo. The following syndromes or conditions are additional exclusion factors:

  16. Treacher-Collins Syndrome
  17. Nager Syndrome
  18. Goldenhar syndrome or hemifacial microsomia plus an occlusal cant of 20 degrees or greater
  19. Absence of vertical ramus (as diagnosed on physical exam or CT)
  20. Absence of zygoma (as diagnosed on physical exam or CT)
  21. Significant orbital asymmetry or micro-ophthalmia (as diagnosed on physical exam or CT)

Sites / Locations

  • John Reinisch, MD
  • Microtia-Congenital Ear Deformity Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

AuriNovo

Arm Description

AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.

Outcomes

Primary Outcome Measures

Safety through assessment of AEs
Safety data will be collected on AE type, frequency and severity, treatment, and the time to resolution.
Efficacy as measured through overall satisfaction scores
Data will be collected to determine the suitability of the AACC to support reconstruction of the outer ear in microtia patients. The following will be used to determine satisfaction; - Surgical Outcomes Questionnaire (scores range from 15 (lowest satisfaction) to 75 (highest satisfaction))
Efficacy as measured through overall satisfaction scores
Data will be collected to determine the suitability of the AACC to support reconstruction of the outer ear in microtia patients. The following will be used to determine satisfaction; - FACE-Q Kids Questionnaire (scores range from 74 (lowest satisfaction) to 296 (highest satisfaction))

Secondary Outcome Measures

Full Information

First Posted
May 19, 2020
Last Updated
May 23, 2023
Sponsor
3DBio Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT04399239
Brief Title
AuriNovo for Auricular Reconstruction
Official Title
A Multicenter, Single Arm, Prospective, Open-Label, Staged Study of the Safety and Efficacy of the AuriNovo Construct for Auricular Reconstruction in Subjects With Unilateral Microtia
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Terminated
Why Stopped
Company decision, not safety related.
Study Start Date
August 9, 2021 (Actual)
Primary Completion Date
May 18, 2023 (Actual)
Study Completion Date
May 18, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
3DBio Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
AuriNovo provides a patient-specific, biological construct for use in the surgical reconstruction of the external ear in people born with microtia Grades II-IV. This Phase 1 / 2A study is being conducted to collect preliminary safety data on microtic ear reconstruction using AuriNovo, fine-tune technical, logistical, surgical, and post-surgical care aspects related to implantation, and to gather preliminary efficacy data including short- and longer-term in vivo duration and biological status of the implant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Microtia
Keywords
ear reconstruction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AuriNovo
Arm Type
Experimental
Arm Description
AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
Intervention Type
Combination Product
Intervention Name(s)
AuriNovo
Other Intervention Name(s)
AACC
Intervention Description
AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
Primary Outcome Measure Information:
Title
Safety through assessment of AEs
Description
Safety data will be collected on AE type, frequency and severity, treatment, and the time to resolution.
Time Frame
3 months
Title
Efficacy as measured through overall satisfaction scores
Description
Data will be collected to determine the suitability of the AACC to support reconstruction of the outer ear in microtia patients. The following will be used to determine satisfaction; - Surgical Outcomes Questionnaire (scores range from 15 (lowest satisfaction) to 75 (highest satisfaction))
Time Frame
3 months
Title
Efficacy as measured through overall satisfaction scores
Description
Data will be collected to determine the suitability of the AACC to support reconstruction of the outer ear in microtia patients. The following will be used to determine satisfaction; - FACE-Q Kids Questionnaire (scores range from 74 (lowest satisfaction) to 296 (highest satisfaction))
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pediatric children 6-11, adolescents 12-16, or adults 17-25 years old Born with unilateral microtia Grade II, III, or IV No previous surgical procedure for auricular reconstruction Have undergone an audiological assessment prior to enrollment and surgeon confirmation that study participation will not preclude future hearing correction options Normal or near normal hairline position Able to adhere to the follow-up schedule and post-surgery care instructions Ability for the subject and/or guardian to understand and give informed consent Healthy subjects with no history of cancer, problematic wound healing, or immune disorders Exclusion Criteria: Previous cochlear implant surgery Patients with prior surgery in the temporal, parietal, or mastoid regions of the affected side that resulted in scarring that may affect the outcome of microtia reconstruction surgery. Sensitivity to broad-spectrum aminoglycoside antibiotics containing any of the following: streptomycin, gentamycin tobramycin, amikacin, kanamycin, neomycin, or plazomicin. Sensitivity to materials of porcine origin including pork products. For subjects with no known exposure to porcine materials including pork products, sensitivity as confirmed at baseline through a positive porcine skin sensitivity test. Patients previously diagnosed/evaluated for any of the following syndromes: CHARGE (Coloboma, Heart defect, choanal Atresia, Retarded growth and development, Genital hypoplasia, Ear anomalies) syndrome, Branchio-oto-renal (BOR) syndrome Patients with renal dysfunction of any etiology Patients with abnormal renal function determined at baseline with a blood test. Patients with a history of keloid formation. Patients with current skin infection. Patients on immunosuppressants. Any cognitive disorders where the patient would not be able to complete subject assessment questionnaires. Lifestyle activities likely to affect healing or ability to adhere to the protocol (e.g., active contact sports and protective gear interferes with wearing post-operative ear protection) Patients requiring chronic use of any headgear (e.g., CPAP) that would interfere with the ability to wear post-operative ear protection. Pregnant females (a negative pregnancy test is required for females with reproductive potential) Female patients who are nursing/lactating Patients of reproductive potential (male and female) unwilling to use effective contraception during the first post-operative year. For this first-in-human study, microtia patients with significant craniofacial asymmetries or deformities from other syndromes will be excluded in order to aid initial assessments of efficacy of AuriNovo. The following syndromes or conditions are additional exclusion factors: Treacher-Collins Syndrome Nager Syndrome Goldenhar syndrome or hemifacial microsomia plus an occlusal cant of 20 degrees or greater Absence of vertical ramus (as diagnosed on physical exam or CT) Absence of zygoma (as diagnosed on physical exam or CT) Significant orbital asymmetry or micro-ophthalmia (as diagnosed on physical exam or CT)
Facility Information:
Facility Name
John Reinisch, MD
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
Microtia-Congenital Ear Deformity Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78240
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

AuriNovo for Auricular Reconstruction

We'll reach out to this number within 24 hrs